Top Page
Harrow Health
(NASDAQ:HROW)
Harrow Health (HROW) vs. SPDR S&P 500 ETF (SPY)
Harrow Health Business Overview & Revenue Model
Harrow Health Earnings Call Summary
Harrow Health Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 227.66M | 199.61M | 130.19M | 88.59M | 72.48M | 48.87M |
| Gross Profit | 169.75M | 150.37M | 90.55M | 63.21M | 54.26M | 34.41M |
| EBITDA | 32.10M | 19.28M | 9.72M | -3.10M | 4.26M | 3.49M |
| Net Income | -10.23M | -17.48M | -24.41M | -14.09M | -18.01M | -3.36M |
Balance Sheet | ||||||
| Total Assets | 345.03M | 388.97M | 312.16M | 157.02M | 98.33M | 57.47M |
| Cash, Cash Equivalents and Short-Term Investments | 52.96M | 47.25M | 82.77M | 101.86M | 50.67M | 32.56M |
| Total Debt | 231.25M | 228.83M | 190.50M | 112.23M | 77.96M | 23.53M |
| Total Liabilities | 295.73M | 319.67M | 241.75M | 130.14M | 87.40M | 30.65M |
| Stockholders Equity | 49.65M | 69.65M | 70.77M | 27.59M | 11.29M | 27.18M |
Cash Flow | ||||||
| Free Cash Flow | -34.38M | -60.88M | -148.71M | -6.07M | -23.43M | -2.09M |
| Operating Cash Flow | 4.04M | -22.20M | 3.84M | 1.71M | 5.08M | -1.10M |
| Investing Cash Flow | -38.66M | -33.16M | -152.55M | -1.74M | -18.69M | -981.00K |
| Financing Cash Flow | 16.62M | 28.53M | 126.53M | 54.14M | 51.47M | 1.43M |
Harrow Health Technical Analysis
Harrow Health Risk Analysis
Harrow Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $1.84B | -572.73 | -3.63% | ― | 132.35% | 97.34% | |
| ― | $1.13B | 9.08 | 18.32% | ― | 1.37% | -18.10% | |
| ― | $2.02B | -121.36 | -2.82% | ― | 38.68% | -160.14% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $944.04M | -7.54 | -15.57% | ― | 2.25% | -301.59% | |
| ― | $1.47B | -8.68 | -16.34% | ― | -1.03% | 8.13% | |
| ― | $1.41B | ― | -18.99% | ― | 47.69% | 69.57% |
Harrow Health Corporate Events
On October 6, 2025, Harrow, Inc. announced leadership changes at its subsidiary ImprimisRx, with Frank Mullery appointed as Chief Executive Officer and Bridseida Cruz as Head of Quality. These appointments are expected to drive the next phase of growth and innovation for ImprimisRx, a national leader in ophthalmic compounding, as part of Harrow’s vision to become a prominent U.S. ophthalmic company. The leadership changes are anticipated to enhance the company’s operational phase, fulfilling unmet needs of U.S. eyecare professionals and benefiting stakeholders by continuing to provide critical, affordable medicines.
The most recent analyst rating on (HROW) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
On September 26, 2025, Harrow, Inc. entered into a New Credit Agreement with Fifth Third Bank for a senior secured revolving credit facility of $40 million, with an additional uncommitted $20 million line of credit. The agreement, maturing in 2030, includes covenants and financial requirements, impacting Harrow’s financial operations and strategic flexibility.
The most recent analyst rating on (HROW) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
On September 26, 2025, Harrow, Inc. hosted its Investor Day, during which the company presented an investor presentation that was also used in subsequent investor meetings. The presentation was made available as part of a Current Report on Form 8-K, but the information is not considered filed under the Securities Exchange Act of 1934 or the Securities Act of 1933.
The most recent analyst rating on (HROW) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
On September 26, 2025, Harrow announced its agreement to acquire Melt Pharmaceuticals, a company specializing in non-opioid, non-IV sedation therapies. This acquisition, subject to customary closing conditions, aims to strengthen Harrow’s portfolio and market presence by integrating Melt’s innovative MELT-300 product, which has shown clinical superiority in sedation without the need for intravenous administration. The acquisition is expected to diversify Harrow’s business, enhance operational synergies, and expand market opportunities, particularly in the U.S. procedural sedation market.
The most recent analyst rating on (HROW) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
On September 8, 2025, Harrow, Inc. entered into a purchase agreement with BTIG, LLC for the sale of $250 million in senior notes due 2030, with a 8.625% interest rate. The company completed the sale of these notes on September 12, 2025, receiving approximately $244 million in net proceeds. Harrow intends to use these funds to prepay existing borrowings, pay exit costs, and for general corporate purposes, including potential strategic business development opportunities. Additionally, Harrow announced the redemption of its 8.625% Senior Notes due 2026, scheduled for October 13, 2025, which will result in their delisting from Nasdaq.
The most recent analyst rating on (HROW) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
On September 8, 2025, Harrow, Inc. announced the pricing of its $250 million offering of 8.625% senior unsecured notes due 2030. The proceeds from this offering are intended to repay existing debts, including a $107.5 million facility with Oaktree Fund Administration and outstanding senior notes, with any remaining funds to be used for general corporate purposes. This strategic financial move is expected to impact Harrow’s operations by reducing existing debt and potentially funding future business development opportunities.
The most recent analyst rating on (HROW) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
On September 5, 2025, Harrow, Inc. entered into a commitment letter with Fifth Third Bank for a new $40 million revolving credit facility. Subsequently, on September 8, 2025, Harrow announced the launch of a private offering to sell $250 million in senior unsecured notes due 2030, with proceeds intended to redeem existing notes, prepay loans, and fund corporate purposes. Additionally, Harrow issued a conditional notice to redeem its 2027 notes, contingent on the offering’s completion, and plans to redeem its 2026 notes. The company also expressed interest in acquiring the remaining equity of Melt Pharmaceuticals, Inc., subject to certain conditions.
The most recent analyst rating on (HROW) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
The recent earnings call of Harrow Health highlighted a period of robust growth and strategic advancements, although it was not without its challenges. The company reported significant revenue increases and strategic alliances, but faced hurdles with the decline in VEVYE revenue and underperformance in its specialty branded portfolio.
On August 21, 2025, Harrow, Inc. announced the appointment of Andrew R. Boll as President, who will continue his roles as Chief Financial Officer and Secretary. Randall E. Pollard was appointed as Chief Accounting Officer, effective September 1, 2025, bringing over 20 years of experience in financial reporting and corporate accounting leadership. The Board also approved amended bylaws, designating the CEO as the principal executive officer and updating officer roles to align with current governance practices.
The most recent analyst rating on (HROW) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Harrow, Inc. is a prominent North American company specializing in ophthalmic disease management solutions, offering a wide array of products aimed at treating various eye conditions, including dry eye disease, cataracts, and retinal diseases.
Harrow announced its second-quarter 2025 financial results, reporting a 30% increase in total revenues to $63.7 million compared to the previous year. The company highlighted significant growth in its VEVYE® and IHEEZO® products, with VEVYE® gaining nearly 3% in market share and 66% sequential prescription growth. Harrow also secured exclusive U.S. commercial rights to Samsung Bioepis’s ophthalmology biosimilar portfolio and acquired rights for BYQLOVI™, a new ophthalmic steroid. The strategic alliance with Apollo Care is expected to enhance patient access and insurance coverage, further driving growth. These developments position Harrow to exceed $280 million in revenue for 2025 and strengthen its market presence.
The most recent analyst rating on (HROW) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.